ライフサイエンスコーパス: Lp-PLA2

1 ty-five percent of participants had abnormal Lp-PLA2.

2 tory response in part by effects elicited by Lp-PLA2.

3 mans is characterized by local production of Lp-PLA2.

4 for apoB, only prava40 led to a reduction in Lp-PLA2 (-15%, p = 0.008) and atorva10 to a decrease in

5 risk of coronary heart disease (CHD), making Lp-PLA2 a potential therapeutic target.

6 Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipase A2 family of enz

7 therapy significantly decreased the level of Lp-PLA2, a vascular-specific, inflammatory enzyme that p

8 ) PLA2G7 single-nucleotide polymorphisms and Lp-PLA2 activity (3 prospective, 2 case-control, 2 cross

9 mg/d was associated with a 20% reduction in Lp-PLA2 activity (P<0.001), whereas Lp-PLA2 rose 3.6% wi

10 V events was similar across all quintiles of Lp-PLA2 activity (Ptrend=0.88).

11 T and PI use were positively associated with Lp-PLA2 activity and mass after adjusting for age, race,

12 Lp-PLA2 activity correlated with several CHD risk marker

13 PLA2G7 variants associated with Lp-PLA2 activity could evaluate whether this relationshi

14 y lipoprotein (LDL), and C-reactive protein, Lp-PLA2 activity in the highest quintile remained indepe

15 Patients with 30-day Lp-PLA2 activity in the highest quintile were at signifi

16 At 30 days, Lp-PLA2 activity is significantly lowered with high-dose

17 Adding Lp-PLA2 activity tertiles to the model improved the pred

18 xamine the association of the following: (1) Lp-PLA2 activity versus cardiovascular biomarkers and ri

19 events for the top versus bottom quartile of Lp-PLA2 activity were 1.61 (95% confidence interval, 1.3

20 Plasma levels of Lp-PLA2 activity were measured at baseline (n=3648) and

21 7 variants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular

22 Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest

23 t of lysophosphatidylcholine, the product of Lp-PLA2 activity, was documented on the mineralization o

24 A379V) showed the strongest association with Lp-PLA2 activity, with VV subjects having 7.2% higher ac

25 eaction, immunohistochemistry, and enzymatic Lp-PLA2 activity.

26 Risk Score tertile had significantly higher Lp-PLA2 activity.

27 er lipoprotein-associated phospholipase A(2)(Lp-PLA2) activity is associated with increased risk of c

28 ted lipoprotein-associated phospholipase A2 (Lp-PLA2), also called platelet-activating factor acetylh

29 Lp-PLA2, also known as platelet-activating factor acetyl

30 Serum levels of Lp-PLA2, an enzyme that hydrolyzes oxidized phospholipid

31 ard ratio of 1.78 for the highest tertile of Lp-PLA2 and 2.53 for the highest category of CRP versus

32 duals with LDL-C <130 mg/dL, those with both Lp-PLA2 and CRP levels in the highest tertile were at th

33 Lp-PLA2 and CRP levels were higher in the 608 cases than

34 Lp-PLA2 and CRP may be complementary in identifying indi

35 Both Lp-PLA2 and CRP were associated with incident CHD after

36 als with LDL-C below the median (130 mg/dL), Lp-PLA2 and CRP were both significantly and independentl

37 ) in human plasma, this review will focus on Lp-PLA2 and human coronary heart disease.

38 er Lp-PLA2 decrease included higher baseline Lp-PLA2 and IL-6 levels, smaller increases in total chol

39 This study has investigated whether Lp-PLA2 and its major enzymatic product, lysophosphatidy

40 The Lp-PLA2 and OxLDL were reduced in statin-treated groups,

41 -PLA2, lysophosphatidylcholine (a product of Lp-PLA2), and C-reactive protein.

42 LDL has been shown to be highly enriched in Lp-PLA2; and in advanced atheroma, Lp-PLA2 levels are hi

43 man lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovascular disease and

44 tinues to build supporting the usefulness of Lp PLA2 as a predictor of coronary events in the general

45 Lp-PLA2 augments the inflammatory response after MI and

46 We evaluated the association between Lp-PLA2, cardiac allograft vasculopathy (CAV) assessed b

47 adults and to determine associations between Lp-PLA2, cardiometabolic risk factors, and subclinical a

48 Lp-PLA2 correlated positively with LDL-C (r=0.36) and ne

49 urther work is necessary to document whether Lp-PLA2 could be considered as a novel target in CAVD.

50 k in Communities study, the relation between Lp-PLA2, CRP, traditional risk factors, and risk for CHD

51 As a specific inhibitor of Lp-PLA2, darapladib has been shown to be protective agai

52 163 levels; factors associated with a larger Lp-PLA2 decrease included higher baseline Lp-PLA2 and IL

53 ce whose bone marrow-derived leukocytes were Lp-PLA2-deficient (bmLp-PLA2 (-/-)).

54 We hypothesized that Lp-PLA2 (encoded by the PLA2G7 gene) is expressed in CAV

55 Recent reports have linked Lp-PLA2 enrichment not only to the most atherogenic of L

56 ladib is an oral, selective inhibitor of the Lp-PLA2 enzyme.

57 Selective inhibition of Lp-PLA2 has been postulated to reduce necrotic core prog

58 Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherog

59 Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyses oxidized low-density lipoproteins in

60 as conducted to describe the distribution of Lp-PLA2 in a cohort of human immunodeficiency virus (HIV

61 to confirm or refute a contributory role for Lp-PLA2 in CHD.

62 ly have data emerged demonstrating a role of Lp-PLA2 in development of advanced coronary artery disea

63 This study tested the role of Lp-PLA2 in healing after MI.

64 A fragment screen was conducted against Lp-PLA2 in order to identify novel inhibitors.

65 The prognostic value of Lp-PLA2 in patients with acute coronary syndromes (ACS)

66 Higher expression of Lp-PLA2 in stenotic aortic valves was confirmed by quant

67 These results support the role for Lp-PLA2 in the mechanism of regional vascular inflammati

68 of lipoprotein-associated phospholipase A2 (Lp-PLA2) in atherosclerosis, partly because of the lack

69 of lipoprotein-associated phospholipase A2 (Lp-PLA2) in calcific aortic valve disease (CAVD).

70 ot definitive proof, of a potential role for Lp PLA2 inhibition in coronary heart disease prevention.

71 Taken together, this study demonstrates that Lp-PLA2 inhibition can effectively prevent diabetes-medi

72 l studies are warranted to determine whether Lp-PLA2 inhibition improves plaque stability and ultimat

73 Systemic Lp-PLA2 inhibition using SB-435495 at 10 mg/kg (i.p.) ef

74 es on the efficacy of darapladib, a specific Lp PLA2 inhibitor, show beneficial changes in plaque mor

75 er effects, or randomized trials of specific Lp-PLA2 inhibitors are needed to confirm or refute a con

76 or lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors may play a role in reducing progress

77 Elevated Lp PLA2 is also associated with stroke and heart failure

78 Lp PLA2 is gaining acceptance as a useful biomarker of c

79 The crystal structure of Lp PLA2 is now available and offers insight into the lin

80 Several studies have confirmed that Lp-PLA2 is an independent risk factor for cardiovascular

81 hypothesis that local coronary production of Lp-PLA2 is enhanced in patients with early coronary athe

82 Lp-PLA2 is highly abnormal in HIV-infected patients and

83 Together, these results demonstrated that Lp-PLA2 is highly expressed in CAVD, and it plays a role

84 Lp-PLA2 is independently associated with progression of

85 Lp-PLA2 is intimately associated with several aspects of

86 Lp-PLA2 is not useful for risk stratification when measu

87 Lp-PLA2 is well placed, whether on an oxidation suscepti

88 Lipoprotein-associated phospholipase A2 (Lp PLA2) is postulated to occupy a key position in the p

89 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel marker and participant in vascular i

90 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme associated primaril

91 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk factor for coronary artery disease (C

92 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker of cardiovascular dise

93 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with the risk of cardiovascular (

94 sophosphatidylcholine, the active product of Lp-PLA2, is associated with endothelial dysfunction.

95 High Lp-PLA2 level was associated with increase in plaque vol

96 Lp-PLA2 level>236 ng/mL (higher tertile) identified a su

97 vation independently predicted the change in Lp-PLA2 level.

98 ally significant predictors of a decrease in Lp-PLA2 level.

99 the lipoprotein-associated phospholipase A2 (Lp-PLA2) level was seen in the statin group, compared wi

100 tently support a relationship between plasma Lp-PLA2 levels and susceptibility to coronary heart dise

101 riched in Lp-PLA2; and in advanced atheroma, Lp-PLA2 levels are highly upregulated, colocalizing with

102 Elevated Lp-PLA2 levels associate with increased risk of cardiova

103 Lp-PLA2 levels correlate with an increased risk of recur

104 In response to MI, Lp-PLA2 levels markedly increased in the circulation.

105 The Lp-PLA2 levels positively correlated with age (r = 0.09)

106 Elevated Lp-PLA2 levels predict CHD events in apparently healthy

107 Arterial Lp-PLA2 levels were similar in patients and control subj

108 ed to greater decreases in sCD14, hsCRP, and Lp-PLA2 levels, compared with EFV/FTC/TDF.

109 were noted for changes in sCD14, hsCRP, and Lp-PLA2 levels.

110 sk in HIV-infected individuals by decreasing Lp-PLA2 levels.

111 Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coronary heart disease

112 e animal models with a human-like pattern of Lp-PLA2 lipoprotein distribution.

113 6-5.19, P=0.012) compared with patients with Lp-PLA2< or =236 ng/mL.

114 artery and coronary sinus for measurement of Lp-PLA2, lysophosphatidylcholine (a product of Lp-PLA2),

115 PI)-based treatment had significantly higher Lp-PLA2 mass and activity than those who were treatment-

116 tid intima-media thickness (cIMT) had higher Lp-PLA2 mass and activity.

117 m (CAC) scores >100 had significantly higher Lp-PLA2 mass than those with lower or nondetectable calc

118 Mean Lp-PLA2 mass was 313 +/- 105 ng/mL and activity 173 +/-

119 sed lipoprotein-associated phospholipase A2 (Lp-PLA2) mass or activity is associated with an increase

120 Lp-PLA2 may be a useful marker for risk of CAV and a the

121 Thus, Lp-PLA2 may be a useful therapeutic target for patients

122 Indeed, Lp-PLA2 may be an important link between lipid homeostas

123 Lp-PLA2 may be used as an additional and more vascular s

124 sma lipoprotein-associated phospholipase A2 (Lp-PLA2), Mercodia oxidized LDL (OxLDL) with antibody 4E

125 In particular, Lp-PLA2 might play an important role in plaque vulnerabi

126 Lp-PLA2 net production in the coronary circulation was h

127 , have been shown to reduce plasma levels of Lp-PLA2, none has been studied in terms of its ability t

128 onary heart disease this is not the case for Lp-PLA2 polymorphisms.

129 Selective inhibition of Lp-PLA2 reduces development of necrotic cores and may re

130 ction in Lp-PLA2 activity (P<0.001), whereas Lp-PLA2 rose 3.6% with pravastatin 40 mg/d (P<0.001).

131 The number of Lp-PLA2 transcripts correlated with several indexes of t

132 Lp-PLA2 was assessed in 341 (25% women, 52% white, 74% o

133 l nonmineralized aortic valves revealed that Lp-PLA2 was increased by 4.2-fold in mineralized aortic

134 Lp-PLA2 was measured in plasma aliquots using an enzyme-

135 To test the functional importance of Lp-PLA2, we generated chimeric mice whose bone marrow-de

136 Overall, mean levels of Lp-PLA2 were lower at 30 days of follow-up than at basel

137 on (lipoprotein-associated phospholipase A2 [Lp-PLA2]) were compared.

138 factors including LDL-C, the association of Lp-PLA2 with CHD was attenuated and not statistically si

139 perienced an ACS event, direct inhibition of Lp-PLA2 with darapladib added to optimal medical therapy

140 ere used to examine the association of serum Lp-PLA2 with incident CHD (myocardial infarction, angina

141 he large macrophage-mediated upregulation of Lp-PLA2 within advanced plaques.